Trial Profile
A First In Human, Open Label, Dose Escalation Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Clinical Activity Profile Of Single Agent RO7119929 (TLR7 Agonist) Administered Orally To Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs RO 7119929 (Primary) ; Tocilizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Colorectal cancer; Ductal carcinoma; Gallbladder cancer; Gastric cancer; Liver cancer; Malignant melanoma; Pancreatic cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Triple negative breast cancer; Uveal melanoma
- Focus Adverse reactions; First in man
- Sponsors Roche
- 19 Apr 2023 Results assessing whether RO7119929 induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients patients, presented at the 114th Annual Meeting of the American Association for Cancer Research
- 19 Apr 2023 Results (At data cut-off 22 April 2022, n=55 ), presented at the 114th Annual Meeting of the American Association for Cancer Research
- 27 Jan 2023 Status changed from active, no longer recruiting to completed.